Stroke prevention in patients with atrial fibrillation (AF) is one pillar of the management of
this common arrhythmia. Substantial advances in the epidemiology and associated …

Objectives To update the EULAR recommendations for the management of systemic lupus
erythematosus (SLE) based on emerging new evidence. Methods An international Task …

FXI (factor XI) and FXII (factor XII) have emerged as targets for new anticoagulants that have
the potential to be both more efficacious and safer than the currently available direct oral …

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute
pulmonary embolism. Important advances have enabled better understanding …

Antiphospholipid syndrome (APS) is an autoimmune prothrombotic disease characterized
by thrombosis and/or pregnancy complications caused by antiphospholipid antibodies …

For most patients, direct oral anticoagulants (DOACs) are preferred over vitamin K
antagonists for stroke prevention in atrial fibrillation and for venous thromboembolism …

During the past decade, direct oral anticoagulants (DOACs) have advanced and simplified
the prevention and treatment of venous thromboembolism (VTE). However, there remains a …

Catastrophic antiphospholipid syndrome (CAPS) is a rare and life-threatening condition
characterized by the persistence of antiphospholipid antibodies and occurrence of multiple …

In clinical practice, the number of patients treated with direct oral anticoagulants (DOACs)
has consistently increased over the years. Since anticoagulant therapy has been associated …

Introduction Antiphospholipid syndrome (APS) is an autoimmune thrombotic disease with
various systemic presentations. This study aimed to identify homogeneous groups of …